Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C28H28N4O3 |
Molecular Weight | 468.5469 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)C[C@@H]1CCN2C=C(C3=C2C=CC=C3)C4=C(C(=O)NC4=O)C5=CN(CCO1)C6=C5C=CC=C6
InChI
InChIKey=ZCBUQCWBWNUWSU-SFHVURJKSA-N
InChI=1S/C28H28N4O3/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24/h3-10,16-18H,11-15H2,1-2H3,(H,29,33,34)/t18-/m0/s1
Molecular Formula | C28H28N4O3 |
Molecular Weight | 468.5469 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/2010/01/WC500068826.pdfCurator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23404115 | https://www.ncbi.nlm.nih.gov/pubmed/19825373 | https://www.ncbi.nlm.nih.gov/pubmed/15380221
Sources: http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/2010/01/WC500068826.pdf
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23404115 | https://www.ncbi.nlm.nih.gov/pubmed/19825373 | https://www.ncbi.nlm.nih.gov/pubmed/15380221
Ruboxistaurin is an orally bioavailable, selective, potent inhibitor of protein kinase C β developed for treating diabetic retinopathy. In vitro and in vivo non-clinical models have demonstrated that Ruboxistaurin decreases PKC β activity and ameliorates many of the effects of PKC β on pathologic processes in the retina. Ruboxistaurin prevents the slowing of retinal blood flow that is observed by fluorescein video angiography in the eyes of diabetic rats. It is also reported to cause regression of retinal neovascularization produced by laser-induced major branch vein occlusions in a porcine model. Ruboxistaurin positively affected the diabetes-induced retinal blood flow abnormalities in a Phase Ib study in diabetic patients. Ruboxistaurin is in phase III clinical trials for the treatment of diabetic nephropathy and diabetic macular edema. Eli Lilly had submitted Ruboxistaurin for approval in the US and the EU; however, the company subsequently discontinued development as it was unable to demonstrate sufficient efficacy
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3045 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15380221 |
5.9 nM [IC50] | ||
Target ID: CHEMBL299 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12954055 |
360.0 nM [IC50] | ||
Target ID: CHEMBL2938 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12954055 |
300.0 nM [IC50] | ||
Target ID: CHEMBL3616 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12749884 |
52.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta. | 1996 Jul 5 |
|
Protein kinase C{alpha}, but not PKC{beta} or PKC{gamma}, regulates contractility and heart failure susceptibility: implications for ruboxistaurin as a novel therapeutic approach. | 2009 Jul 17 |
|
Selective inhibition of protein kinase C beta(2) attenuates inducible nitric oxide synthase-mediated cardiovascular abnormalities in streptozotocin-induced diabetic rats. | 2009 Oct |
|
Inhibition of protein kinase Cbeta does not improve endothelial function in type 2 diabetes. | 2010 Aug |
|
Blockade of PKC-beta protects HUVEC from advanced glycation end products induced inflammation. | 2010 Dec |
|
A PKC-beta inhibitor treatment reverses cardiac microvascular barrier dysfunction in diabetic rats. | 2010 Jul |
|
Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. | 2010 Nov 24 |
|
Comprehensive analysis of kinase inhibitor selectivity. | 2011 Oct 30 |
|
Docetaxel Facilitates Endothelial Dysfunction through Oxidative Stress via Modulation of Protein Kinase C Beta: The Protective Effects of Sotrastaurin. | 2015 May |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23404115
32 mg/day
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19825373
HUVECs co-cultured with fibroblasts were cultivated in the presence or absence of various concentrations of ruboxistaurin (0.1 and 1 mkM) plus VEGF (10 ng/ml) at days 1, 4, 7 and 9. The ruboxistaurin was dissolved in dimethyl sulfoxide (DMSO, final concentration of DMSO was 0.1%). DMSO (0.1%) was added to the non-drug control (control group). At day 11, cells were fixed in 70% ethanol. The cells were incubated with diluted primary antibody (mouse anti-human CD31, 1 : 4000) for 1 h at 37 C, and with the secondary antibody (goat anti-mouse IgG alkaline phosphataseconjugated antibody, 1 : 500) for 1 h at 37 C. Visualization was achieved using 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:26:36 GMT 2023
by
admin
on
Fri Dec 15 16:26:36 GMT 2023
|
Record UNII |
721809WQCP
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C2089
Created by
admin on Fri Dec 15 16:26:37 GMT 2023 , Edited by admin on Fri Dec 15 16:26:37 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
RUBOXISTAURIN
Created by
admin on Fri Dec 15 16:26:37 GMT 2023 , Edited by admin on Fri Dec 15 16:26:37 GMT 2023
|
PRIMARY | |||
|
C66524
Created by
admin on Fri Dec 15 16:26:37 GMT 2023 , Edited by admin on Fri Dec 15 16:26:37 GMT 2023
|
PRIMARY | |||
|
153999
Created by
admin on Fri Dec 15 16:26:37 GMT 2023 , Edited by admin on Fri Dec 15 16:26:37 GMT 2023
|
PRIMARY | |||
|
721809WQCP
Created by
admin on Fri Dec 15 16:26:37 GMT 2023 , Edited by admin on Fri Dec 15 16:26:37 GMT 2023
|
PRIMARY | |||
|
3533
Created by
admin on Fri Dec 15 16:26:37 GMT 2023 , Edited by admin on Fri Dec 15 16:26:37 GMT 2023
|
PRIMARY | |||
|
m9693
Created by
admin on Fri Dec 15 16:26:37 GMT 2023 , Edited by admin on Fri Dec 15 16:26:37 GMT 2023
|
PRIMARY | Merck Index | ||
|
C099154
Created by
admin on Fri Dec 15 16:26:37 GMT 2023 , Edited by admin on Fri Dec 15 16:26:37 GMT 2023
|
PRIMARY | |||
|
8108
Created by
admin on Fri Dec 15 16:26:37 GMT 2023 , Edited by admin on Fri Dec 15 16:26:37 GMT 2023
|
PRIMARY | |||
|
DTXSID00168775
Created by
admin on Fri Dec 15 16:26:37 GMT 2023 , Edited by admin on Fri Dec 15 16:26:37 GMT 2023
|
PRIMARY | |||
|
CHEMBL91829
Created by
admin on Fri Dec 15 16:26:37 GMT 2023 , Edited by admin on Fri Dec 15 16:26:37 GMT 2023
|
PRIMARY | |||
|
169939-94-0
Created by
admin on Fri Dec 15 16:26:37 GMT 2023 , Edited by admin on Fri Dec 15 16:26:37 GMT 2023
|
PRIMARY | |||
|
DB11829
Created by
admin on Fri Dec 15 16:26:37 GMT 2023 , Edited by admin on Fri Dec 15 16:26:37 GMT 2023
|
PRIMARY | |||
|
100000089175
Created by
admin on Fri Dec 15 16:26:37 GMT 2023 , Edited by admin on Fri Dec 15 16:26:37 GMT 2023
|
PRIMARY | |||
|
SUB25202
Created by
admin on Fri Dec 15 16:26:37 GMT 2023 , Edited by admin on Fri Dec 15 16:26:37 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT | |||
|
EXCRETED UNCHANGED |
FECAL
|
||
|
EXCRETED UNCHANGED |
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
at 4h
PLASMA
|
||
|
METABOLITE -> PARENT |
FECAL
|
||
|
METABOLITE -> PARENT |
MAJOR
FECAL
|
||
|
METABOLITE -> PARENT |
at 8h
PLASMA
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Tmax | PHARMACOKINETIC |
|
ORAL ADMINISTRATION |
|
||
Biological Half-life | PHARMACOKINETIC |
|
ORAL ADMINISTRATION |
|
||